LAIgnd: Revolutionizing Drug Discovery with Advanced AI-Driven Molecule Generation

De novo molecular generation is crucial for advancing drug discovery and chemical research. This accelerates the search for new drug candidates and deepens our understanding of molecular diversity. The development of deep learning has propelled and expedited the de novo molecular generation. Generative networks, particularly Variational Autoencoders (VAEs), can randomly produce new molecules and modify molecular structures to enhance specific chemical properties, which are essential for advancing drug discovery. Although VAEs offer numerous advantages, they are hindered by limitations that affect their capacity to optimize properties and decode syntactically valid molecules. To address these challenges, we present LAIgnd, a de novo drug molecule generation model that implements a custom β-CVAE architecture conditioned on protein sequences and SELFIES input. Extensive experiments have shown that LAIgnd generates a wide variety of valid, novel, and effective molecules for complex and simple diseases, demonstrating its robustness and generalization capabilities. Additionally, by employing molecular docking, toxicity, similarity, and synthetic accessibility experiments, we demonstrated the drug-likeness and effectiveness of the generated molecules. The ability of our model to generate novel and diverse compounds was illustrated by a case study focusing on Lung Cancer. A total of four hundred (400) molecules were generated by LAIgnd, with a high number of molecules exhibiting strong inhibitory activity against the Epidermal Growth Factor receptor, as indicated by binding affinities. LAIgnd provides new insights into future directions to enhance therapeutics for complex and simple diseases by generating high-quality multi-target molecules for drug discovery. Key words: De novo molecular generation, Drug discovery, Variational Autoencoders (VAEs), SELFIES, Protein sequences. CISDI Journal Reference Format Obi, E.D., Yentumi, J.A., Mbatuegwu, D., Omotuyi, O.I., Ajayi, O.O. & Nwokoro, A. (2024): LAIgnd: Revolutionizing Drug Discovery with Advanced AI-Driven Molecule Generation. Computing, Information Systems, Development Informatics & Allied Research Journal. Vol 15 No 4, Pp 1-10. Available online at www.isteams.net/cisdijournal. dx.doi.org/10.22624/AIMS/CISDI/V15N3P4

Authors

Publication Details

Journal
Advances in Multidisciplinary & Scientific Research Journal Publication
Published
2024-11-27
DOI
https://doi.org/10.22624/aims/cisdi/v15n3p4
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

LAIgnd: Revolutionizing Drug Discovery with Advanced AI-Driven Molecule Generation

Olulope Olufemi Ajayi, Olaposi Idowu Omotuyi, E. Obi, J.A. Yentumi et al.
Advances in Multidisciplinary & Scientific Research Journal Publication
Computational Drug Discovery Methods
article

LAIgnd: Revolutionizing Drug Discovery with Advanced AI-Driven Molecule Generation

Olulope Olufemi Ajayi, Olaposi Idowu Omotuyi, E. Obi, J.A. Yentumi, D. Mbatuegwu, A. Nwokoro
article en

Abstract

De novo molecular generation is crucial for advancing drug discovery and chemical research. This accelerates the search for new drug candidates and deepens our understanding of molecular diversity. The development of deep learning has propelled and expedited the de novo molecular generation. Generative networks, particularly Variational Autoencoders (VAEs), can randomly produce new molecules and modify molecular structures to enhance specific chemical properties, which are essential for advancing drug discovery. Although VAEs offer numerous advantages, they are hindered by limitations that affect their capacity to optimize properties and decode syntactically valid molecules. To address these challenges, we present LAIgnd, a de novo drug molecule generation model that implements a custom β-CVAE architecture conditioned on protein sequences and SELFIES input. Extensive experiments have shown that LAIgnd generates a wide variety of valid, novel, and effective molecules for complex and simple diseases, demonstrating its robustness and generalization capabilities. Additionally, by employing molecular docking, toxicity, similarity, and synthetic accessibility experiments, we demonstrated the drug-likeness and effectiveness of the generated molecules. The ability of our model to generate novel and diverse compounds was illustrated by a case study focusing on Lung Cancer. A total of four hundred (400) molecules were generated by LAIgnd, with a high number of molecules exhibiting strong inhibitory activity against the Epidermal Growth Factor receptor, as indicated by binding affinities. LAIgnd provides new insights into future directions to enhance therapeutics for complex and simple diseases by generating high-quality multi-target molecules for drug discovery. Key words: De novo molecular generation, Drug discovery, Variational Autoencoders (VAEs), SELFIES, Protein sequences. CISDI Journal Reference Format Obi, E.D., Yentumi, J.A., Mbatuegwu, D., Omotuyi, O.I., Ajayi, O.O. & Nwokoro, A. (2024): LAIgnd: Revolutionizing Drug Discovery with Advanced AI-Driven Molecule Generation. Computing, Information Systems, Development Informatics & Allied Research Journal. Vol 15 No 4, Pp 1-10. Available online at www.isteams.net/cisdijournal. dx.doi.org/10.22624/AIMS/CISDI/V15N3P4

Advances in Multidisciplinary & Scientific Research Journal PublicationVol. 15(4)
Openalex Percentile: Top 74%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.